Pulmonix LLC, USA   Report issue

For profit Phase 2
Founded: Greensboro NC United States (1998)

Organization Overview

First Clinical Trial
2013
NCT01890265
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

PulmonIx LLC, USA

Active Ingredients

Drugs in Phase 2 Trials (1)

pamrevlumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1